This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 10.94% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
by Zacks Equity Research
Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Comfort Systems USA and Boeing are part of the Zacks Bull and Bear of the Day article.
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
by Indrajit Bandyopadhyay
Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
Reasons to Hold Baxter International (BAX) in Your Portfolio
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
by Zacks Equity Research
Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.
Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand
by Zacks Equity Research
Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.
Baxter (BAX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 2.33% and 2.28%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Baxter (BAX) Q4 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Baxter (BAX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
Reasons to Retain Baxter International (BAX) in Your Portfolio
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business
by Zacks Equity Research
Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.
3 Medical Products Stocks to Consider as Earnings Approach
by Shaun Pruitt
These top-rated Zacks Medical sector stocks are very attractive ahead of their quarterly reports on Thursday, November 2 with now looking like an ideal time to invest.
What's in Store for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) first-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.
Medical Product Stocks' Q3 Earnings Due on Nov 1: SYK & More
by Indrajit Bandyopadhyay
Third-quarter results of Medical Product companies are likely to reflect a year-over-year decline. Let's see how SYK, COR, BAX, FMS and XRAY fare this time around.
Stryker (SYK) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Stryker's (SYK) third-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.
Cencora (COR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) fiscal fourth-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
BAX vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
BAX vs. SYK: Which Stock Is the Better Value Option?
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day
by Santanu Roy
NeoGenomics and SolarEdge Technologies are part of the Zacks Bull and Bear of the Day article.
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
by Indrajit Bandyopadhyay
Here we pick three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye
by Zacks Equity Research
Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.